跳至主要内容
临床试验/NCT00140504
NCT00140504已完成不适用

Preventing Adverse Drug Events With PatientSite

Dana-Farber Cancer Institute2 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2003年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
800
试验地点
2
主要终点
To prevent adverse drug events with PatientSite.

研究概览

简要总结

This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.

详细描述

  • A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
  • Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
  • To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
  • This study will run for 12 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients >18
  • Patients that receive a new prescription
  • Proficient in spoken and written english

排除标准

  • 未提供

结局指标

主要结局

To prevent adverse drug events with PatientSite.

时间窗: 3 years

次要结局

  • Improve patient satisfaction(3 years)
  • better utilization of services(3 years)
  • improve patient-clinician communication(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Saul N. Weingart, MD, PhD

VP for Quality Improvement and Patient Safety

Dana-Farber Cancer Institute

研究点 (2)

Loading locations...

相似试验